BRCA1

BRCA1
Name	BRCA1
Chromosome	17q21
Protein length	1863 amino acids
Synonyms	BROVCA1, RNF53

BRCA1 BRCA1 is a human tumor suppressor protein involved in maintenance of genomic integrity and regulation of DNA damage responses. Discovered in the early 1990s through positional cloning efforts that involved groups at institutions such as University of Utah, Myriad Genetics, University of Cambridge, Massachusetts General Hospital, and Mayo Clinic, BRCA1 has been extensively studied in the contexts of hereditary breast and ovarian cancer syndromes. Research on BRCA1 intersects with clinical genetics programs at Memorial Sloan Kettering Cancer Center, molecular biology laboratories at Cold Spring Harbor Laboratory, and international consortia including ENCODE and The Cancer Genome Atlas.

Structure and molecular function

BRCA1 encodes a 1863–amino acid protein characterized by an N-terminal RING finger domain that interacts with the E3 ubiquitin ligase BARD1 and a C-terminal BRCT domain that recognizes phosphorylated peptide motifs; structural studies have been performed at facilities such as European Molecular Biology Laboratory and Max Planck Institute. High-resolution structures derived from crystallography groups at Stanford University and University of Oxford revealed how BRCT repeats mediate interactions with phosphorylated partners like CtIP and Abraxas, while NMR and cryo-EM efforts at MIT and University of California, San Francisco helped map intrinsically disordered regions that bind transcriptional regulators including RNA polymerase II subunits studied at National Institutes of Health. BRCA1 forms multiprotein complexes—most notably the BRCA1-A, BRCA1-B, and BRCA1-C complexes—whose composition was elucidated through proteomics initiatives at Scripps Research Institute and Broad Institute; these complexes include partners such as BRIP1, PALB2, RAD50, and MRE11A. Post-translational modifications such as phosphorylation by ATM and ATR, ubiquitination coordinated with BARD1, and SUMOylation characterized in studies at University of Edinburgh regulate BRCA1 localization to sites of DNA damage and interactions with chromatin remodelers like SWI/SNF components analyzed at Johns Hopkins University.

Role in DNA repair and genomic stability

BRCA1 is central to double-strand break repair by homologous recombination, a pathway dissected in functional assays at Rockefeller University and Harvard Medical School, where BRCA1 promotes end resection through recruitment of nucleases including EXO1 and DNA2 and coordinates RAD51 filament formation via mediators such as PALB2 and RAD51AP1. Cell-cycle control involving checkpoints mediated by CHK1 and CHK2 kinases studied at Dana-Farber Cancer Institute is influenced by BRCA1-dependent signaling that integrates with replication stress responses characterized by groups at European Genome-phenome Archive. Loss of BRCA1 function leads to chromosomal instability phenotypes—chromosomal translocations, aneuploidy, and micronuclei—observed in cytogenetic work at University of Toronto and Cold Spring Harbor Laboratory and linked to tumorigenesis pathways investigated at National Cancer Institute and Fred Hutchinson Cancer Research Center.

BRCA1 mutations and cancer risk

Germline deleterious variants in BRCA1 were first associated with hereditary breast and ovarian cancer in linkage studies involving families cataloged at Roswell Park Comprehensive Cancer Center and University of Toronto, with founder mutations identified in populations studied at Icelandic Cancer Registry, Ashkenazi Jewish community cohorts at Sheba Medical Center, and regional registries such as Kaiser Permanente research programs. Pathogenic variants—including frameshifts, nonsense mutations, and large rearrangements—confer markedly increased lifetime risks for breast and ovarian cancers, as quantified in epidemiological studies at Columbia University and University of Pennsylvania. Somatic alterations in BRCA1 occur in sporadic tumors characterized by genomic profiling in The Cancer Genome Atlas and influence tumor phenotypes in studies at University College London and Institut Curie. Modifier loci identified through genome-wide association studies at Wellcome Trust Sanger Institute and survival analyses from European Society for Medical Oncology cohorts further refine risk estimates.

Clinical testing and genetic counseling

Clinical BRCA1 testing evolved from single-site assays at Myriad Genetics to multigene panel testing performed by clinical laboratories accredited by College of American Pathologists and regulated by Clinical Laboratory Improvement Amendments. Genetic counseling frameworks developed by professional bodies such as National Society of Genetic Counselors and American Society of Clinical Oncology guide pre- and post-test discussions that address penetrance estimates, variant interpretation using guidelines from American College of Medical Genetics and Genomics, and management strategies recommended by organizations like National Comprehensive Cancer Network. Population-based screening initiatives piloted in United Kingdom National Health Service programs and community outreach projects at St. Jude Children's Research Hospital explore cascade testing in families tracked via registries at Cancer Research UK and biobanks such as UK Biobank.

Therapeutic implications and targeted treatments

Tumors with BRCA1 deficiency exhibit sensitivity to PARP inhibitors, a therapeutic class developed through collaborations among pharmaceutical companies including AstraZeneca, Pfizer, and academic groups at Oxford University and Dana-Farber Cancer Institute; landmark clinical trials such as those conducted by NCI and cooperative groups like Gynecologic Oncology Group established efficacy in BRCA1-mutant cancers. Platinum-based chemotherapies evaluated at MD Anderson Cancer Center show enhanced activity in BRCA1-deficient tumors, and mechanisms of resistance involving secondary BRCA1 reversion mutations have been characterized in tumor sequencing studies at Memorial Sloan Kettering Cancer Center and Broad Institute. Emerging strategies combining immune checkpoint inhibitors—studied in trials at Johns Hopkins University and Vanderbilt University Medical Center—with DNA-damage response inhibitors targeting ATR, ATM, and CHK1 from biotech firms such as Bayer and Merck aim to overcome resistance. Gene-editing and gene-therapy approaches using technologies pioneered at CRISPR Therapeutics and research labs at University of California, Berkeley are under preclinical investigation.

Model organisms and research studies

Functional models of BRCA1 have been developed across species: knockout and conditional alleles in mice generated at Jackson Laboratory and studied at Cold Spring Harbor Laboratory recapitulate mammary and ovarian phenotypes; zebrafish models at Max Planck Institute provide developmental insights; and Drosophila studies at University of Cambridge illuminate conserved DNA repair processes. Large-scale screens—CRISPR and RNAi—performed by consortia including Broad Institute and Wellcome Sanger Institute identified genetic interactions and synthetic-lethal partners such as PARP1, RAD51, and POLQ. Population cohorts in longitudinal studies at Framingham Heart Study and cancer registries at Surveillance, Epidemiology, and End Results Program contributed genotype–phenotype correlations, while structural biology consortia at European Molecular Biology Laboratory and clinical trial networks including European Organisation for Research and Treatment of Cancer continue to advance translational research.

Category:Human proteins